Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD33-CD28-OX40-ζ CAR
- Development stage
- Unknown
- Lead developer
- Creative Biolabs
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a third-generation chimeric antigen receptor (CAR) construct designed to target CD33-expressing cells. It incorporates an anti-CD33 single-chain variable fragment (scFv) for antigen recognition, and intracellular signaling domains from CD28, OX40, and CD3-zeta (ζ). This combination of co-stimulatory domains (CD28 and OX40) with the primary signaling domain (CD3-zeta) is intended to enhance T-cell activation, proliferation, persistence, and anti-tumor activity. It is engineered into cytokine-induced killer (CIK) cells or T cells for adoptive cell therapy, primarily investigated for acute myeloid leukemia (AML).
- Other names
- CD33-CD28-OX40-ζ CAR
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD28 (Cluster of Differentiation 28)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on anti-CD33-CD28-OX40-ζ CAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD33-CD28-OX40-ζ CAR.